Search Results
Your search for ,NOt matches 22378 pages
Showing 3751 - 3800Expert Point of View: Stephen Lam Chan, MD
Invited discussant of the IMbrave050 trial, Stephen Lam Chan, MD, of Chinese University of Hong Kong, put the study into context. “After curative treatment, recurrence remains a big problem [in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or...
IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma
Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...
Israeli Surgical Oncology Leader Dov Zippel, MD, Considers the Evolving Landscape of Cancer Care in a Small Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Dov Zippel, MD, a surgical oncologist at Sheba Medical Center in Tel Hashomer, Israel, where he is Head of the Meirav Breast Center. Dr. Zippel is the current President of ...
Tumor Mutational Burden and Outcomes in Patients With Advanced Cancers Treated With Immune Checkpoint Inhibitors
In a study reported in JAMA Network Open, Charu Aggarwal, MD, MPH, and colleagues found that patients with advanced solid cancers and a high tumor mutational burden (TMB-H) had improved overall survival with immune checkpoint inhibitor therapy vs those with a low tumor mutational burden (TMB-L)....
Novel Bispecific Antibody for Multiple Myeloma Shows High Response Rates in Early Trial
The bispecific antibody REGN5459 achieved a 90.5% overall response rate when given at the two highest doses in patients with relapsed or refractory multiple myeloma, according to the results of a phase I/II clinical trial.1 Although preliminary, the results of this first-in-human trial for the...
Radical Cystectomy vs Trimodality Therapy for Muscle-Invasive Bladder Cancer
In a retrospective analysis reported in The Lancet Oncology, Zlotta et al found that trimodality therapy was associated with similar outcomes compared to radical cystectomy in patients with muscle-invasive bladder cancer. Study Details The study involved 722 patients with clinical stage T2–T4N0M0...
Partnering With Patients: The Cornerstone of Cancer Care and Research
The health and well-being of our clinicians, our communities, and our care systems need vigilance now more than ever to ensure we keep pace with the effects of change that is also advancing our medicine. When clinicians or patients talk about health care, they might mention frustrations with forms ...
Organizations Team Up to Improve Cancer Care in Rural Appalachia
The Appalachian Community Cancer Alliance (ACCA) has launched a lung cancer screening initiative to improve cancer care in rural Appalachia. Home to nearly 26 million people, the Appalachian region includes all of West Virginia and parts of 12 other states, and it has a 10% higher cancer mortality...
Study Analyzes Relationship Between Cancer Survivors’ Tobacco Use, Symptom Burden, and Motivation to Quit Smoking
Investigators have found that current smoking and vaping may be associated with a higher burden of symptoms among adult cancer survivors but that these symptoms may not have had an impact on the desire to quit smoking. The new study was published by Price et al in Cancer. Background Continued...
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory B-Cell Lymphoma
On May 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific CD20-directed CD3 T-cell engager epcoritamab-bysp (Epkinly) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from...
Exercise, Wellness Interventions in Early Breast Cancer Demonstrate Measurable Benefits—Even Economic Ones
Specialized exercise and wellness programs significantly elevated physical well-being and quality of life among patients with breast cancer while reducing the use of health-care resources in new research presented at the 2023 American Society of Breast Surgeons Annual Meeting. In one multicenter...
Specialist Palliative Care for Patients Undergoing Major Abdominal Surgery for Cancer
In a single-center trial reported in JAMA Surgery, Shinall et al found that specialist palliative care did not improve quality of life or survival vs usual care in patients undergoing nonpalliative major abdominal surgery for cancer. Study Details In the trial, 235 patients scheduled for specified...
Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer
Researchers have found that individuals in early and middle adulthood who have a body mass index (BMI) indicating that they have overweight or obesity may be at an increased risk of developing gastrointestinal cancer, according to a new study published by Loomans-Kropp and Umar in JAMA Network...
Trastuzumab/Pertuzumab Plus Neoadjuvant Paclitaxel or Endocrine Therapy in Hormone Receptor–Positive, HER2-Positive Early Breast Cancer
In a German phase II trial (WSG-TP-II) reported in JAMA Oncology, Gluz et al found that the addition of neoadjuvant paclitaxel monotherapy to trastuzumab/pertuzumab resulted in a higher pathologic complete response (pCR) rate in patients with hormone receptor–positive, HER2-positive early breast...
Cancer-Specific Mortality Rates Vary Widely Across the Globe, Study Finds
Investigators have found that in the majority of countries studied, the recent mortality rates for all major cancer types have decreased except for lung cancer among female patients and hepatic cancer among male patients—where increasing rates were observed in most countries, according to a novel...
Patients With Cervical Cancer May Be at Higher Risk for Urinary Tract Infections After Radical Hysterectomies
Patients with early-stage cervical cancer may have an increased risk of developing catheter-associated urinary tract infections following radical hysterectomies if they had a history of smoking or used catheters for more than 7 days postsurgery, according to a new study by Mercadel et al in the...
HPV Self-Collection Kits May Increase Cervical Cancer Screenings Among Underscreened, Underserved Patients
Researchers have found that mailing human papillomavirus (HPV) self-collection kits in addition to offering scheduling assistance to underscreened, underserved patients may increase the rate of cervical cancer screenings compared with scheduling assistance alone, according to a new study published...
Combined Delivery of DNX-2401 Plus Pembrolizumab May Be Safe and Effective in Patients With Recurrent Glioblastoma
Intratumoral delivery of the engineered oncolytic virus DNX-2401 in combination with subsequent immunotherapy with pembrolizumab may be safe and effective at improving survival outcomes in patients with recurrent glioblastoma, according to a study published by Nassiri et al in Nature Medicine....
Patients With Cancer May Prefer Telemedicine Appointments Over In-Person Visits When Both Are Available
Investigators have found that telemedicine may consistently outperform in-person visits for cancer care when assessed for access to care, provider response, and patient experience, according to a new study published by Patel et al in JNCCN–Journal of the National Comprehensive Cancer Network....
Long-Term Risk Prediction for Invasive Breast Cancer: AI System Plus Volumetric Density on Screening Mammography
In a study reported in the Journal of Clinical Oncology, Vachon et al found that the combination of an artificial intelligence (AI) imaging algorithm, together with measures of breast density on mammography screening, were capable of long-term prediction of risk of invasive breast cancer. As stated ...
Patient-Reported Outcomes From the NRG Oncology/RTOG 0815 in Intermediate-Risk Prostate Cancer
In an analysis of the phase III NRG Oncology/RTOG 0815 study reported in the Journal of Clinical Oncology, Benjamin Movsas, MD, and colleagues found few differences in patient-reported outcomes among patients with intermediate-risk prostate cancer receiving short-term total androgen suppression...
Addition of Short-Term ADT to Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer
As reported in the Journal of Clinical Oncology by Daniel J. Krauss, MD, and colleagues, the phase III NRG Oncology/RTOG 0815 study showed no significant improvement in overall survival with the addition of short-term androgen-deprivation therapy (ADT) to dose-escalated radiotherapy in patients...
President Biden Announces Intent to Nominate Monica M. Bertagnolli, MD, as Director of the NIH
In a statement released by The White House on May 15, President Joe Biden announced his intent to nominate Monica M. Bertagnolli, MD, as Director of the National Institutes of Health (NIH), the world’s preeminent biomedical research organization. As the statement makes clear, Dr. Bertagnolli is a...
Young Native Hawaiians and Pacific Islanders May Face Highest Rates of Cancer Mortality
Investigators have found that young Native Hawaiian and Pacific Islander patients may experience the highest rates of cancer mortality of any racial group in the United States among those aged 20 to 49 years. The new data were published by Haque et al in the Journal of the National Cancer...
Cabozantinib in Combination With Nivolumab and Ipilimumab May Slow Progression of Advanced Renal Cell Carcinoma
The targeted kinase inhibitor cabozantinib plus a two-drug immunotherapy combination of nivolumab and ipilimumab may be capable of slowing cancer progression in patients with advanced renal cell carcinoma who received no prior lines of therapy, according to a study published by Choueiri et al in...
Ibrutinib and Rituximab vs Fludarabine, Cyclophosphamide, and Rituximab in Previously Untreated Patients With CLL
As reported in The Lancet Oncology by Peter Hillmen, MBChB, PhD, and colleagues, an interim analysis of the UK phase III FLAIR trial has shown significantly improved progression-free survival with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab (FCR) in previously untreated...
Interruption of Adjuvant Endocrine Therapy to Attempt Pregnancy in Women With Breast Cancer
In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with an increased short-term risk of breast cancer events among women with hormone...
Lenalidomide in Previously Treated Children With Low-Grade Gliomas
In a Children’s Oncology Group phase II trial reported in the Journal of Clinical Oncology, Katherine E. Warren, MD, and colleagues found that lenalidomide showed activity in children with pilocytic astrocytomas and optic pathway gliomas who did not respond to initial therapy. As noted by the...
Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide in Patients With Metastatic Prostate Cancer Initiating ADT
In an analysis of the final results of two STAMPEDE platform phase III trials reported in The Lancet Oncology, Gerhardt Attard, PhD, and colleagues found that the addition of enzalutamide to abiraterone plus prednisolone did not appear to improve survival outcomes and was associated with worse...
Novel Calculator May Identify Patients With Favorable-Prognosis Hematologic Cancers
Researchers have developed a calculator that may be capable of identifying patients who have multiple myeloma and light-chain amyloidosis with more benign profiles and, consequently, better prognoses, according to a novel study published by Burgos et al in the Journal of Clinical Oncology. The...
Prognostic Factors Associated With Survival in Platinum-Resistant Ovarian Cancer
Overall survival time was doubled in women with recurrent platinum-resistant ovarian cancer who have BRCA1/2 mutations, who were treated with PARP inhibitors, and whose tumors were homologous repair–deficient (HRD-test–positive), according to a study that examined prognostic factors for survival in ...
Novel Immunotherapy Combination Explored in Platinum-Resistant Ovarian Cancer
Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with platinum-resistant or -refractory ovarian cancer, in the ongoing phase Ib C-800 study presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Bruno...
ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer
Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...
Expert Point of View: Carol Aghajanian, MD
Carol Aghajanian, MD, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center, New York, commented on the final analysis of NOVA for The ASCO Post. She highlighted the difficulty in truly measuring overall survival in recurrent ovarian cancer. Dr. Aghajanian also ...
NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer
After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators...
GOG 3026: Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer
In patients with recurrent low-grade serous ovarian cancer, treatment with ribociclib plus letrozole was not only active, but led to outcomes that are comparable to those achieved with current agents—with a particularly striking 19-month duration of response—according to Brian M. Slomovitz, MD,...
Expert Point of View: Debra L. Richardson, MD and Joyce F. Liu, MD, MPH
Debra L. Richardson, MD, Associate Professor and Chief of the Section of Gynecologic Oncology, Oklahoma TSET Phase I Program, at the Stephenson Cancer Center, University of Oklahoma, Oklahoma City, discussed the emerging field of antibody-drug conjugates at a session on platinum-resistant ovarian...
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the...
SGO Presentations Explore Inequitable Access to Clinical Trials and Its Impact on Survival
Two studies presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer underscore the importance of enrolling patients with gynecologic cancer on clinical trials and of assuring trial access to racial minorities. One study found a statistically significant...
Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma
The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023...
Expert Point of View: Rebecca Arend, MD, MSH and Ilaria Colombo, MD
“Endometrial cancer is the most frequently diagnosed gynecologic malignancy in the United States, and it is the only one where the mortality has actually risen over the past 40 years,” noted Rebecca Arend, MD, MSH, Associate Professor at the University of Alabama and Associate Scientist in the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Highlights of the SGO 2023 Annual Meeting on Women’s Cancer
The sun was out, and the weather was beautiful for the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer held in Tampa, Florida, in March 2023. Participants came from across the world for this second hybrid gathering since the COVID-19 pandemic to share ongoing advances in ...
An Incidental Finding of Cancer Likely Saved My Life
Except for a ganglion cyst that had mysteriously popped up on the palm of my right hand in the winter of 2016, I appeared to be in excellent health. I had never had any serious illnesses in my then 55 years and rarely even got colds. If the annoying cyst hadn’t interfered with my normal daily...
Personalized Mind-Body Medicine in Integrative Oncology
Guest Editor’s Note: Substantial evidence supports the value of practices that focus on the interactions among the mind, body, and behavior for promoting health and well-being. In this article, Kavita K. Mishra, MD, MPH, summarizes a clinical model for personalized mind-body medicine in cancer care ...
ED Visits Among Patients With Cancer: Three Main Messages
There are “three main messages” to be gleaned from a study about emergency department visits and unplanned hospitalizations among patients with cancer, the study’s lead author, Amir Alishahi Tabriz, MD, PhD, MPH, told The ASCO Post. Dr. Alishahi is Assistant Member, Department of Health Outcomes...
Study Finds Cancer-Related Emergency Department Visits Increased by 67%, Mainly Because of Uncontrolled Pain
Emergency department (ED) visits by patients with cancer increased by 67.1% between the start of 2012 and the end of 2019, compared with an increase of just 7.5% in cancer incidence, according to a recent study in JAMA Network Open.1 Factors identified as possible explanations for the...
Cancer Immunology and Immunotherapy: Principles and Practice
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, we begin a new series of articles on cancer immunology and immunotherapy, in which the authors discuss how immunotherapy has become a major pillar of...
Enfortumab Vedotin-ejfv With Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
On April 3, 2023, enfortumab vedotin-ejfv with pembrolizumab was granted accelerated approval for patients with locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy.1,2 Enfortumab vedotin-ejfv is an antibody-drug conjugate targeting nectin 4....
ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations
ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family...
